Loading...
ABSI logo

Absci CorporationNasdaqGS:ABSI Stock Report

Market Cap US$1.2b
Share Price
US$7.41
US$9.5
22.0% undervalued intrinsic discount
1Y168.5%
7D1.9%
1D
Portfolio Value
​
View

Absci Corporation

NasdaqGS:ABSI Stock Report

Market Cap: US$1.2b

Absci (ABSI) Stock Overview

A clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. More details

ABSI fundamental analysis
Snowflake Score
Valuation1/6
Future Growth2/6
Past Performance0/6
Financial Health5/6
Dividends0/6

Rewards

Revenue is forecast to grow 46.54% per year

Risk Analysis

Has less than 1 year of cash runway

Volatile share price over the past 3 months compared to the US market

Shareholders have been diluted in the past year

Currently unprofitable and not forecast to become profitable over the next 3 years

+ 1 more risk

ABSI Community Fair Values

Create Narrative

See what 41 others think this stock is worth. Follow their fair value or set your own to get alerts.

Analyst Price Targets

Top Community Narratives

View all narratives

Absci Corporation Competitors

Price History & Performance

Summary of share price highs, lows and changes for Absci
Historical stock prices
Current Share PriceUS$7.41
52 Week HighUS$8.17
52 Week LowUS$2.24
Beta2.46
1 Month Change45.29%
3 Month Change146.18%
1 Year Change168.48%
3 Year Change335.88%
5 Year Changen/a
Change since IPO-65.68%

Recent News & Updates

Analysis Article • Jun 19

Absci (ABSI) Stock Could Be 63% Overvalued After Leerink Starts Coverage

Absci (ABSI) drew fresh attention after Leerink initiated coverage, highlighting the company’s AI native, clinical stage drug pipeline, including ABS-20 and ABS-201, and pointing to 2026 as a potentially important clinical data year. See our latest analysis for Absci. Absci’s recent coverage has coincided with strong momentum, with a 30 day share price return of 60.04% and a 90 day share price return of 150.34%. The 1 year total shareholder return of 169.45% points to strong longer term...
Seeking Alpha • Jun 09

Absci Corporation: A Big Binary Approaching In Alopecia

Summary ABSI's ABS-201 is in development for androgenetic alopecia, in a trial called Headline, with some data due in June, but initial efficacy data is due in H2'26. ABSI's trial aims for higher prolactin receptor occupancy than competitor HMI-115, but proof-of-concept in AGA remains uncertain given mixed competitor results. Cash reserves of $125.7M may last into H1'28, but dilution risk is elevated with a $1B+ market cap and recent ATM activity. Competitive pressure in androgenetic alopecia exists, although ABS-201's mechanism also gives it potential in treating gray hair and endometriosis. Read the full article on Seeking Alpha

Recent updates

Analysis Article • Jun 19

Absci (ABSI) Stock Could Be 63% Overvalued After Leerink Starts Coverage

Absci (ABSI) drew fresh attention after Leerink initiated coverage, highlighting the company’s AI native, clinical stage drug pipeline, including ABS-20 and ABS-201, and pointing to 2026 as a potentially important clinical data year. See our latest analysis for Absci. Absci’s recent coverage has coincided with strong momentum, with a 30 day share price return of 60.04% and a 90 day share price return of 150.34%. The 1 year total shareholder return of 169.45% points to strong longer term...
Seeking Alpha • Jun 09

Absci Corporation: A Big Binary Approaching In Alopecia

Summary ABSI's ABS-201 is in development for androgenetic alopecia, in a trial called Headline, with some data due in June, but initial efficacy data is due in H2'26. ABSI's trial aims for higher prolactin receptor occupancy than competitor HMI-115, but proof-of-concept in AGA remains uncertain given mixed competitor results. Cash reserves of $125.7M may last into H1'28, but dilution risk is elevated with a $1B+ market cap and recent ATM activity. Competitive pressure in androgenetic alopecia exists, although ABS-201's mechanism also gives it potential in treating gray hair and endometriosis. Read the full article on Seeking Alpha
Analysis Article • Apr 04

We Think Absci (NASDAQ:ABSI) Needs To Drive Business Growth Carefully

There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...
Analysis Article • Jul 19

Does Absci (NASDAQ:ABSI) Have A Healthy Balance Sheet?

Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...
Seeking Alpha • Jan 13

Absci Looks Cheap And Positioned For Growth With AMD's AI Backing

Summary Absci recently received a $20 million PIPE investment from AMD that improves its runway and R&D platform with AI. ABS-101 appears to be ABSI’s main drug candidate for IBD. However, ABS-201 for hair loss and ABS-301 for solid tumors offer additional sizeable TAMs if successful. ABSI’s AI models and wet lab data seem quite promising for discovering further antibodies that could be highly differentiated from other competitors. ABSI trades at a cheap P/B of 1.5, so I don’t think the shares have priced in the potential of its partnership with AMD yet. My main concern is that ABSI operates with highly speculative technologies, and its candidates remain in the early R&D stages. Read the full article on Seeking Alpha
Seeking Alpha • Nov 20

Absci Corporation: Struggling To Live Up To Its AI Promise

Summary Absci Corporation's stock has rebounded due to new collaborations, but skepticism about AI's impact on drug discovery keeps it heavily underwater from its IPO price. Absci uses AI and wet lab technologies to speed up drug discovery, aiming to reduce preclinical periods to under two years. Despite partnerships with Merck, AstraZeneca, and others, Absci's revenue remains minimal, and it has no advanced pipeline assets yet. With a market cap just over $300 million and cash runway into 1H27, Absci is a speculative play in the AI drug discovery space. An analysis around Absci Corporation follows in the paragraphs below. Read the full article on Seeking Alpha
Analysis Article • Nov 13

Is Absci (NASDAQ:ABSI) A Risky Investment?

Legendary fund manager Li Lu (who Charlie Munger backed) once said, 'The biggest investment risk is not the volatility...
Seeking Alpha • Oct 29

Absci: Embryonic Pipeline Looks Expensive Relative To Peers

Summary Absci's differentiated drug discovery platform could create significant shareholder value long term. The company has a long and expensive path to traverse before it can prove the merits of its approach though. While cash burn is currently limited, Absci's operations are ramping, meaning increased costs could begin to pressure the share price in the future. Absci has largely avoided the growing pessimism towards AI-enabled drug discovery companies and is beginning to look expensive relative to peers as a result. Read the full article on Seeking Alpha
Seeking Alpha • Oct 03

Absci: AI-Driven Platform Could Establish Best-In-Class TL1A Drug Targeting Profile

Summary Absci Corporation's initiation of a phase 1 study using ABS-101 for the treatment of patients with IBD expected early 2025, with interim data to be released in the 2nd half of 2025. ABS-101 aims to differentiate itself with unique features like de novo antibody creation, multiparameter lead optimization, and reverse immunology, potentially offering superior potency and dosing flexibility. The global Crohn's Disease treatment market is expected to reach $17.80 billion by 2033. The ulcerative colitis treatment market is expected to reach $14.77 billion by 2033. Read the full article on Seeking Alpha
Seeking Alpha • Jul 28

Absci Corporation Leverages AI For Rapid Drug Discovery And Promising Partnerships

Summary Absci Corporation uses IDCP technology to quickly produce high-quality drug candidates in as little as six weeks, reducing costs and improving research success rates. The company has promising candidates in inflammatory bowel disease, dermatology, and immuno-oncology, attracting major partnerships with over $900 million in deal value and royalties. ABSI focuses on three therapeutic areas: inflammatory bowel disease, dermatology, and immuno-oncology. Investors should be aware of the high risks due to the speculative nature of AI-driven drug discovery and potential funding needs. Still, ABSI trades at a reasonable valuation, making it a sound speculative "buy" for investors aware of biotech's inherent risks. Read the full article on Seeking Alpha
Analysis Article • Jun 17

Is Absci (NASDAQ:ABSI) A Risky Investment?

The external fund manager backed by Berkshire Hathaway's Charlie Munger, Li Lu, makes no bones about it when he says...
Seeking Alpha • May 16

Absci: 'AI' Tag Keeping Company Afloat While Searching For Right Formula

Summary Absci Corporation, an AI-driven drug discovery company, has seen its share price plummet after its IPO in July 2021. Nearly all AI-driven drug discovery companies have struggled with overall share price performance since IPO. Absci's stock has been picking up - +250% across the past six months - thanks to investment in the sector, and a recently agreed partnership with AstraZeneca. Merck is another Big Pharma partner, but these deals don't guarantee revenues and with development programs preclinical, it's difficult to assign much value. Without its "AI" tag, Absci would likely be a $100m - $200m market cap valuation company. The company may show its mettle in time, but the prospect of near term revenues, or further upside, seems remote in 2024. Read the full article on Seeking Alpha
Seeking Alpha • Feb 27

Absci: Differentiated Antibody Discovery Play

Summary Absci combines generative AI with scalable wet lab technologies to improve antibody discovery, with the eventual goal of in silico drug design. While Absci's stock has benefitted from AI hype in recent months, the company has substance. Its approach to antibody drug development is unique and could have advantages. Absci's valuation is still reasonable given the company's long-term potential, but the stock price is likely to be tied to AI sentiment in the near term, creating downside risk. Read the full article on Seeking Alpha

Shareholder Returns

ABSIUS BiotechsUS Market
7D1.9%1.3%1.4%
1Y168.5%31.4%25.7%

Return vs Industry: ABSI exceeded the US Biotechs industry which returned 31.4% over the past year.

Return vs Market: ABSI exceeded the US Market which returned 25.7% over the past year.

Price Volatility

Is ABSI's price volatile compared to industry and market?
ABSI volatility
ABSI Average Weekly Movement15.2%
Biotechs Industry Average Movement10.5%
Market Average Movement7.2%
10% most volatile stocks in US Market16.8%
10% least volatile stocks in US Market3.1%

Stable Share Price: ABSI's share price has been volatile over the past 3 months compared to the US market.

Volatility Over Time: ABSI's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
2011140Sean McClainwww.absci.com

Absci Corporation, a clinical-stage biopharmaceutical company, develops various antibody therapeutics in the United States. Its preclinical development programs include ABS-101, which is in Phase 1 clinical trial for the treatment of inflammatory bowel disease; ABS-201, an anti-prolactin receptor (PRLR) antibody, which is phase 1/2a clinical trial for treating androgenic alopecia; ABS-301 for the treatment of immuno-oncology; and ABS-501 for treating oncology. Absci Corporation has collaboration agreements with PrecisionLife, Memorial Sloan Kettering Cancer Center, Twist Bioscience, Owkin, Oracle Corporation, and Advanced Micro Devices, Inc. for joint research and development activities.

Absci Corporation Fundamentals Summary

How do Absci's earnings and revenue compare to its market cap?
ABSI fundamental statistics
Market capUS$1.16b
Earnings (TTM)-US$118.44m
Revenue (TTM)US$1.84m
629.2x
P/S Ratio
-9.8x
P/E Ratio

Is ABSI overvalued?

See Fair Value and valuation analysis

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
ABSI income statement (TTM)
RevenueUS$1.84m
Cost of RevenueUS$83.63m
Gross Profit-US$81.79m
Other ExpensesUS$36.64m
Earnings-US$118.44m

Last Reported Earnings

Mar 31, 2026

Next Earnings Date

n/a

Earnings per share (EPS)-0.76
Gross Margin-4,454.96%
Net Profit Margin-6,450.76%
Debt/Equity Ratio0.2%

How did ABSI perform over the long term?

See historical performance and comparison

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2026/06/22 13:34
End of Day Share Price 2026/06/18 00:00
Earnings2026/03/31
Annual Earnings2025/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Absci Corporation is covered by 15 analysts. 11 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Michael RyskinBofA Global Research
Kambiz YazdiBTIG
Vamil DivanGuggenheim Securities, LLC